ReviewJournal of pharmacokinetics and pharmacodynamics2005
Non-linear mixed effects modeling - from methodology and software development to driving implementation in drug development science.
Review in Journal of pharmacokinetics and pharmacodynamics, 2005. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 32 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
32 citing papers in PubMed, 99 citations in OpenAlex.
- Model-Based Approach to Predict Adherence to Protocol During Antiobesity Trials.Journal of clinical pharmacology · 2018Trial
- Estimation of population pharmacokinetic parameters of saquinavir in HIV patients with the MONOLIX software.Journal of pharmacokinetics and pharmacodynamics · 2007Trial
- Advancing pharmacometrics in Africa-Transition from capacity development toward job creation.CPT: pharmacometrics & systems pharmacology · 2025Review
- A tutorial for model-based evaluation and translation of cardiovascular safety in preclinical trials.CPT: pharmacometrics & systems pharmacology · 2024Article
- A workflow for the joint modeling of longitudinal and event data in the development of therapeutics: Tools, statistical methods, and diagnostics.CPT: pharmacometrics & systems pharmacology · 2022Article
- Practical identifiability in the frame of nonlinear mixed effects models: the example of the in vitro erythropoiesis.BMC bioinformatics · 2021Article
- Clinical pharmacology applications in clinical drug development and clinical care: A focus on Saudi Arabia.Saudi pharmaceutical journal : SPJ : the official publication of the Saudi Pharmaceutical Society · 2020Review
- Opioids and alpha-2-agonists for analgesia and sedation in newborn infants: protocol of a systematic review.Systematic reviews · 2020Article
- Pharmacokinetic Modeling of Ceftiofur Sodium Using Non-linear Mixed-Effects in Healthy Beagle Dogs.Frontiers in veterinary science · 2019Article
- Fuzzy Evaluation of Pharmacokinetic Models.Computational intelligence and neuroscience · 2018Article
- A Longitudinal HbA1c Model Elucidates Genes Linked to Disease Progression on Metformin.Clinical pharmacology and therapeutics · 2016Article
- Measuring the individual benefit of a medical or behavioral treatment using generalized linear mixed-effects models.Statistics in medicine · 2016Article
- Logic-Based and Cellular Pharmacodynamic Modeling of Bortezomib Responses in U266 Human Myeloma Cells.The Journal of pharmacology and experimental therapeutics · 2015Article
- The inverse problem in mathematical biology.Mathematical biosciences · 2015Review
- Article
- Lewis Sheiner ISoP/UCSF Lecturer Award: From Drug Use to Statistical Models and Vice Versa.CPT: pharmacometrics & systems pharmacology · 2014Article
- Powers of the likelihood ratio test and the correlation test using empirical bayes estimates for various shrinkages in population pharmacokinetics.CPT: pharmacometrics & systems pharmacology · 2014Article
- Largazole pharmacokinetics in rats by LC-MS/MS.Marine drugs · 2014Article
- Prediction of shrinkage of individual parameters using the bayesian information matrix in non-linear mixed effect models with evaluation in pharmacokinetics.Pharmaceutical research · 2013Article
- Pharmacokinetic modeling of P-glycoprotein function at the rat and human blood-brain barriers studied with (R)-[11C]verapamil positron emission tomography.EJNMMI research · 2012Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 2 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Few scientific contributions have made significant impact unless there was a champion who had the vision to see the potential for its use in seemingly disparate areas-and who then drove active implementation. In this paper, we present a historical summary of the development of non-linear mixed effects (NLME) modeling up to the more recent extensions of this statistical methodology. The paper places strong emphasis on the pivotal role played by Lewis B. Sheiner (1940-2004), who used this statistical methodology to elucidate solutions to real problems identified in clinical practice and in medical research and on how he drove implementation of the proposed solutions. A succinct overview of the evolution of the NLME modeling methodology is presented as well as ideas on how its expansion helped to provide guidance for a more scientific view of (model-based) drug development that reduces empiricism in favor of critical quantitative thinking and decision making.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.